The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial by unknown
JOURNAL OF 
NEUROINFLAMMATION
Singh et al. Journal of Neuroinflammation 2014, 11:1
http://www.jneuroinflammation.com/content/11/1/1RESEARCH Open AccessThe effect of intravenous interleukin-1 receptor
antagonist on inflammatory mediators in
cerebrospinal fluid after subarachnoid
haemorrhage: a phase II randomised controlled trial
Navneet Singh1,2, Stephen J Hopkins1*, Sharon Hulme2, James P Galea1,2, Margaret Hoadley1, Andy Vail1,3,
Peter J Hutchinson4, Samantha Grainger4, Nancy J Rothwell2, Andrew T King1 and Pippa J Tyrrell1Abstract
Background: Interleukin-1 (IL-1) is a key mediator of ischaemic brain injury induced by stroke and subarachnoid
haemorrhage (SAH). IL-1 receptor antagonist (IL-1Ra) limits brain injury in experimental stroke and reduces plasma
inflammatory mediators associated with poor outcome in ischaemic stroke patients. Intravenous (IV) IL-1Ra crosses
the blood–brain barrier (BBB) in patients with SAH, to achieve cerebrospinal fluid (CSF) concentrations that are
neuroprotective in rats.
Methods: A small phase II, double-blind, randomised controlled study was carried out across two UK neurosurgical
centres with the aim of recruiting 32 patients. Adult patients with aneurysmal SAH, requiring external ventricular
drainage (EVD) within 72 hours of ictus, were eligible. Patients were randomised to receive IL-1Ra (500 mg
bolus, then a 10 mg/kg/hr infusion for 24 hours) or placebo. Serial samples of CSF and plasma were taken
and analysed for inflammatory mediators, with change in CSF IL-6 between 6 and 24 hours as the primary
outcome measure.
Results: Six patients received IL-1Ra and seven received placebo. Concentrations of IL-6 in CSF and plasma were
reduced by one standard deviation in the IL-1Ra group compared to the placebo group, between 6 and 24 hours, as
predicted by the power calculation. This did not reach statistical significance (P = 0.08 and P = 0.06, respectively), since
recruitment did not reach the target figure of 32. No adverse or serious adverse events reported were attributable
to IL-1Ra.
Conclusions: IL-1Ra appears safe in SAH patients. The concentration of IL-6 was lowered to the degree expected,
in both CSF and plasma for patients treated with IL-1Ra.Background
Aneurysmal subarachnoid haemorrhage (SAH) accounts
for 5% of all strokes, but 25% of stroke-related mortality
[1,2]. Of those who survive the initial bleed, up to one-third
may develop delayed cerebral ischaemia (DCI) [3]. The
mechanism of DCI remains unclear, but vasospasm and
inflammation may be involved [4-6] in its progression
to a worse outcome, with nimodipine having only a* Correspondence: Steve.Hopkins@manchester.ac.uk
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stated.modest impact [7]. Inflammation is a key process in
cerebral ischaemia [8] and is driven by the cytokine
interleukin-1 (IL-1). IL-1 upregulates the expression of
IL-6, which triggers local inflammation and activation of
the systemic acute phase response. IL-6 concentrations
are elevated in the cerebrospinal fluid (CSF) of patients
after SAH and higher concentrations of CSF IL-6 are seen
in patients with worse clinical outcomes [9].
The naturally occurring selective antagonist of IL-1,
IL-1 receptor antagonist (IL-1Ra) blocks all known actions
of IL-1 and is a promising candidate as a treatment
for cerebral ischaemia [10,11]. Intracerebroventriculartd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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experimentally induced brain injury in rodents, including
ischaemia [12,13], trauma [14], and perinatal hypoxia [15].
In experimental cerebral ischaemia, IL-1Ra is protective
when administered intravenously (IV) [16] or subcutane-
ously (SC) [17], and when administered up to 3 hours after
onset [18]. Intravenously administered IL-1Ra crosses the
blood–brain barrier (BBB) and can be found in CSF of
SAH patients at concentrations that are effective in limiting
brain injury in rodents [16]. In ischaemic stroke patients,
IV IL-1Ra reduces peripheral inflammation (plasma IL-6,
white cell count, and C-reactive protein, CRP) measured 7
days after stroke [19].
Up to 25% of patients with SAH require temporary
external CSF drainage [1] to treat hydrocephalus. This
offers a unique opportunity to study changes in brain
physiology and pharmacology in patients, where these
are reflected in CSF. Using this approach, we have shown
that IV IL-1Ra crosses the BBB [16] and that experimen-
tally therapeutic CSF concentrations can be achieved
within 45 minutes of IV administration [20].
The aim of this study was to determine whether IV
IL-1Ra reduces the concentration of mediators of in-
flammatory activity in the circulation and CSF.
Methods
Patient inclusion criteria and data collection
This was a two-centre (Salford Royal NHS Foundation
Trust, Salford, and Addenbrooke’s Hospital, Cambridge,
UK), randomised, double-blind, placebo-controlled trial.Table 1 Eligibility criteria for study patients
Inclusion criteria Exclu
Aged 18 years or above. Know
Patients with confirmed aneurysmal SAH who have had an
EVD inserted as part of their clinical care, that is expected




IL-1Ra or placebo can be administered within 72 hours from ictus. Previ
Patients are likely to remain resident within the study centre for
the next 7 days.
Previ
IL-1R
Normal renal function (serum creatinine <177 μmol L-1). Know
devic
of th
Willing and able to give informed consent or consent available
from a patient’s personal representative (usually the next of kin)
for study inclusion including agreement in principle to receive









CI, Chief Investigator; EVD, External ventricular drain; IL, interleukin; IL-1Ra, interleuk
necrosis factor.Ethical and appropriate competent authority approvals
were obtained. The inclusion and exclusion criteria are
shown in Table 1.
Informed consent was obtained from the patient or the
patient’s representative. Demographic and clinical details
were recorded. SAH severity was graded clinically using
the World Federation of Neurosurgical Societies (WFNS)
score [21] and radiologically using the Fisher grade [22].
The randomisation service was provided by an independ-
ent third-party professional company, Sealed Envelope
(London, UK; http://www.sealedenvelope.com). After
consent the patient was randomised, baseline clinical
assessment was performed, and CSF (2 mL) and plasma
(5 mL) samples were taken. This was immediately followed
by administration of placebo or IL-1Ra. IL-1Ra was injected
as Kineret, a recombinant, non-glycosylated form of human
IL-1Ra [23]. An IV bolus of 500 mg, given over 1 minute,
was immediately followed by a 10 mg/kg/hr infusion
over 24 hours. CSF and plasma samples were taken at
6, 12, 24 (end of infusion), 36, 48, and 72 hours. Adverse
event reporting was carried out according to Medicines
and Healthcare Products Regulatory Agency (MHRA) and
sponsor regulations.
Cytokine assays
Blood samples were collected into tubes containing
ethylenediaminetetraacetic acid (EDTA) and centrifuged
at 2,000 g at 4°C for 15 minutes. Plasma was frozen
at −70°C. The CSF was sampled from the patient’s
external ventricular drain (EVD), after discarding the firstsion criteria
n or suspected infection at the time of consideration for the study.
n allergy to Escherichia coli or any of the constituents of the study
cation as established from the patient themselves, reliable representative,
nical records.
ous or existing treatment with IL-1Ra.
ous or current treatment with medication suspected of interacting with
a, such as TNF-α inhibitors.
n to have participated in a clinical trial of an investigational agent or
e in the previous 30 days or for the period determined by the protocol
e study the patient has taken part in.
n pregnancy or breast-feeding.
ally significant concurrent medical condition which, at the CI’s
esignee’s) discretion, could affect the safety, tolerability, or efficacy in this
or would interfere with participation, administration of study treatment,
sessment of outcomes. For example, pre-existing malignancy.
ous inclusion in the current study.
lity or unwillingness of patient or patient’s personal representative to
written informed consent.
in-1 receptor antagonist; SAH, subarachnoid haemorrhage; TNF, tumour
Total screened
254 total (222 SRFT +32 CUH)

















18 administrative; 15 
clinical; 5 declined 
consent
5 withdrawn:
3 ineligible; 1 EVD 
blocked; 1 withdrawn 
consent
Figure 1 Flow chart showing the screening and recruitment numbers at Salford Royal Foundation Trust and Addenbrooke’s Hospital.
CUH, Cambridge University Hospitals; EVD, external ventricular drain; SRFT, Salford Royal Foundation Trust.
Table 2 Assay performance
Analyte Plasma CSF
Sensitivity (pg/mL) Inter-assay CV range
(QC concentration range)
Sensitivity (pg/mL) Inter-assay CV range
(QC concentration range)
IL-1Ra 16 8.2 to 3.2 (360 to 10,009 pg/mL) Same assay as for plasma
IL-1α 6.1 9.0 to 4.2 (25 to 366 pg/mL) 4.75 6.6 to 9.2 (20 to 800 pg/mL)
IL-1β 1.3 10.3 to 6.3 (17.5 to 146 pg/mL) 0.48 30.3 to 10.9 (1.3 to 10.9 pg/mL)
IL-6 1.7 5.9 to 2 (41 to 322 pg/mL) 17 7.1 to 2.6 (213 to 1,229 pg/mL)
IL-8 4.7 7.9 to 16 (109 to 975 pg/mL) 17 8.9 to 15.8 (185 to 9,152 pg/mL)
IL-10 1.3 10.3 to 6.26 (7.5 to 146 pg/mL) 0.82 10.6 to 5.5 (5.16 to 232 pg/mL)
MCP-1 45 19.5 to 11.3 (207 to 1,759 pg/mL) 147 (19 to 6.5 (9,303 to 11,275 pg/mL)
TNF-α 0.35 6.7 to 7.0 (16.8 to 159 pg/mL) 2.5 25 to 15.8 (4.3 to 28.1 pg/mL)
CRP 350 14.8 to 1 (9.2 to 97 mg/L) ND
The assay performance data is only for assays used in this study. The lowest sensitivity of the assays is shown and represents either the non-sample value (+2 SD),
or the lowest point on the standard curve. Inter-assay CVs are shown from the lowest to the highest concentration of QCs (three or four) that were included in all
assays. CRP, C-reactive protein; CV, coefficient of variation; IL, interleukin; IL-1Ra, interleukin-1 receptor antagonist; MCP-1, monocyte chemoattractant protein-1;
ND, not determined; QC, quality control; TNF, tumour necrosis factor.
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Mean age (range) (years) 54 (40 to 69) 50 (42 to 61) 58 (40 to 69)
Male/female 3/10 1/6 2/4
WFNS grade
1 1 1 0
2 5 4 1
3 0 0 0
4 3 1 2
5 4 1 3
Fisher grade
3 3 2 1
4 10 5 5
Aneurysm location
Anterior circulation 9 5 4
Posterior circulation 4 2 2
an = 13, as this includes all patients in whom an infusion was started. One
patient did not complete the infusion; therefore analyses included only 12
patients. IL-1Ra, interleukin-1 receptor antagonist; WFNS, World Federation of
Neurosurgical Societies.
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were measured by enzyme-linked immunosorbent assay
(ELISA), as described elsewhere [19]. Monocyte chemo-
attractant protein-1 (MCP-1), IL-1β, IL-6, IL-8, IL-10,
and tumour necrosis factor-alpha (TNF-α) concentrations
in plasma and CSF, and CRP in plasma, were measured
using Luminex bead technology (Luminex, Austin, TX,
USA). Bio-Plex COOH beads (Bio-Rad Laboratories,
Hemel Hempstead, UK) were coupled to Pelikine anti-
IL-1β (catalogue number, Cat: M9334) anti-IL-6 (Cat:
M191602), anti-IL-8 (Cat: M191802), anti-IL-10 (Cat:
M191002), or anti-TNF-α (Cat: M192302) monoclonal
antibodies (Mast Group, Bootle, UK), R&D anti-IL-1α
(Cat: 840201) or anti-MCP-1 (Cat: 840204) antibodies
(R&D Systems, Minneapolis, MN, USA), or Biodesign
anti-CRP monoclonal antibody (Biodesign anti-CRP;
Cat: M86842M, clone C2), using the Bio-Plex amine
coupling kit (Cat: 171–406001). Detection antibodies
were Pelikine anti-IL-1β (Cat: M193404), anti-IL-6 (Cat:
M191604), anti-IL-8 (Cat: M191804), and anti-TNF-α (Cat:Table 4 Adverse and serious adverse events
Placebo IL-1Ra
Fluctuating GCS Raised ICP; h
Desaturation; cardiac arrhythmia; meningitis Chest sepsis
IV line infection; chest infection; focal seizure Ventilator-as
Leaking wounda
Acute agitationa; pyrexia of unknown origina
aThe 18 adverse and serious adverse events are shown for the five participants that
CRP, C-reactive protein; GCS, Glasgow Coma Scale; ICP, intracranial pressure; IL-1Ra,M192304) from Mast Group, anti IL-1α (Cat: M193404) or
anti-MCP-1 (Cat: 840205) from R&D Systems. The plasma
IL-6, IL-8, IL-10, IL-1β, MCP-1, and TNF-α assays were
conducted as a 7-plex, using 15% horse serum, 5% bovine
serum, and 1% mouse serum in high performance ELISA
buffer (HPE; Pelikine) as a diluent. CSF assays were
conducted as a 4-plex (IL-1α, IL-1β, IL-10, and TNF-α)
in HPE with 1% horse serum, or a 3-plex (IL-6, IL-8, and
MCP-1) in HPE. All standards were calibrated against
current National Institute for Biological Standards and
Control (NIBSC, South Mimms, UK) standards. Plasma
CRP was measured in a single-plex competitive assay,
with 10% horse serum, 5% bovine serum, and 1%
mouse serum diluent in Tris-buffered saline. The
competitor was CRP (P100-0; SCIPAC, Sittingbourne,
UK) that had been biotinylated with Pierce EZ-Link
Sulfo-NHS-LC-LC-Biotin (Pierce, Rockford, IL, USA).
The assay was calibrated with respect to NIBSC human
CRP (NIBSC; 85/506). Binding of biotinylated CRP
was assessed, following addition of R-phycoerythrin
streptavidin (Jackson ImmunoResearch Laboratories Inc,
Stratech, Newmarket, UK; Cat: 016-110-084), using a
Bio-Plex 200 system. Multiplex assay diluents were
matched to plasma or CSF, with three or four quality
controls (QCs) for each analyte. The assay performance
across the assays in this study is provided in Table 2, in
terms of sensitivity and inter-assay coefficient of variation
(CV) for these QCs.
Statistical analysis
The primary outcome measure was the area under the
curve (AUC) for CSF IL-6 concentration, between 6 and
24 hours from the start of the infusion, adjusted for
baseline. Values were log-transformed before analysis and
adjustment was achieved by subtraction of the baseline
value from values at all time points prior to calculation of
AUC. Comparisons between the two treatment groups
were made using Student’s t-test. Similar analyses were
carried out for IL-1α, IL-1β, IL-8, IL-10, MCP-1, TNF-α,
and CRP. Statistical analyses were performed with Stata
version 12 (StataCorp, College Station, TX, USA). The
target sample size was intended to include 16 participants
per treatment group, including replacement of participantsypotensiona
; focal seizures cardiac arrhythmia; increased urine output; increased CRPa
sociated pneumonia
received placebo and the three that received IL-1Ra, in whom they occurred.
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Figure 2 CSF and plasma IL-6 concentrations for 12 participants over 24 hours from the start of infusion. (a) CSF IL-6 and (b) plasma IL-6
concentrations. Solid symbols and lines represent patients that received IL-1Ra. Open symbols and dashed lines represent patients that received
placebo. CSF, cerebrospinal fluid; IL, interleukin; IL-1Ra, interleukin-1 receptor antagonist.
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hours from the start of infusion. This sample size gave 80%
power at the 5% significance level to detect differences
of one standard deviation in outcomes between treatment
groups, similar to that seen for ischaemic stroke patients
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Figure 3 Change from baseline for CSF IL-6, plasma IL-6, and plasma
and (c) plasma CRP. Solid symbols and lines represent patients that received I
placebo. CSF, cerebrospinal fluid; CRP, C-reactive protein; IL, interleukin; IL-1RaResults
Recruitment and baseline characteristics
A total of 254 patients with SAH were admitted to the
centres between June 2009 and July 2010. Of these, 56
patients had a confirmed aneurysm and required EVD
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(b)
CRP for 12 participants over 72 hours. (a) CSF IL-6, (b) plasma IL-6,
L-1Ra. Open symbols and dashed lines represent patients that received
, interleukin-1 receptor antagonist.
Table 5 Analysis of baseline-adjusted AUC from 6 to 24 hours for all outcome measures
Placebo IL-1Ra
Mediator Location Raw Adjusted Raw Adjusted Difference P value
IL-6 CSF 107.3 0.2 111.0 −12.6 12.8 (−2.1 to 27.7) 0.08
Plasma 37.7 −3.7 49.7 −22.3 18.6 (−0.6 to 37.7) 0.06
IL-8 CSF 114.8 4.8 104.7 −2.3 7.1 (−5.4 to 19.5) 0.23
Plasma 37.8 6.4 39.8 −0.3 6.7 (−4.9 to 18.3) 0.23
IL-10 CSF 14.6 −6.3 25.0 −8.1 1.8 (−8.6 to 12.2) 0.70
Plasma 6.7 0.5 9.1 −17.1 17.6 (4.3 to 30.9) 0.01
MCP-1 CSF 139.8 1.5 145.4 −4.0 5.5 (−3.9 to 15.0) 0.22
Plasma 68.7 −4.3 79.2 −4.0 −0.3 (−14.0 to 13.3) 0.96
CRP Plasma 65.2 −1.6 84.5 −0.5 −1.1 (−10.3 to 8.1) 0.79
Figures are the mean AUC for the natural logarithm of each marker plotted against time from 6 to 24 hours. Both ‘raw’ (actual values) and baseline-adjusted
(subtracting the rectangular area defined by the height of the baseline reading across the 18-hour period) are presented. The mean difference (95% CI) and
associated P value are given for the adjusted values. AUC, area under the curve; CRP, C-reactive protein; CSF, cerebrospinal fluid; IL, interleukin; IL-1Ra, interleukin-1
receptor antagonist; MCP-1, monocyte chemoattractant protein-1.
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were recruited into the trial: seven patients received
placebo, six patients received IL-1Ra, and five patients
were withdrawn from the study prior to randomisation.
One patient who received placebo did not complete
the 24-hour infusion and analyses were based on the
12 patients in whom the infusion was completed (six
placebo, six IL-1Ra). A total of 38 potentially eligible
patients were not recruited. Table 3 summarises the base-
line characteristics of each treatment group. There were
no adverse or serious adverse events attributable to the




Good (GOS 4 to 5) Poor (GOS 1 to 3)Changes in plasma and CSF IL-6 following IL-1Ra
administration
The mean CSF IL-6 concentration, prior to infusion was
1,001 pg/mL (range 42 to 2,698 pg/mL). The mean plasma
IL-6 concentration in all patients at this time point was
69 pg/mL (range 3 to 469 pg/mL). The CSF IL-6 con-
centrations reduced over the first 24 hours from the
start of infusion in all six of the active group and in
three of the six controls (Figure 2a). A similar pattern
occurred for plasma IL-6 concentrations, with reductions
for five of the six active compared with two of the five
control participants (Figure 2b). Samples of CSF were not
available for three participants at 48 hours and five
participants at 72 hours, and plasma samples were not
available for two participants at 72 hours, but the 72-hour
CSF and plasma IL-6 kinetics are shown for the remaining
participant samples in Figure 3.Placebo 5 1
IL-1Ra 5 1
Total 10 2
GOS, Glasgow Outcome Score; IL-1Ra, interleukin-1 receptor antagonist; SAH,
subarachnoid haemorrhage.Changes in other measures of inflammation
Plasma and CSF values for IL-1β, IL-1α, and TNF-α were
near or below the limits of detection for most samples.
Details of AUC from 6 to 24 hours for other outcomemeasures, both unadjusted (raw) and adjusted for baseline,
are given in Table 5. The baseline-adjusted AUC difference
for IL-6 in CSF was 12.8, which is essentially a difference
of one standard deviation (12.3) for the combined data.
This is consistent with the difference anticipated from the
power calculation, for the numbers recruited. Similarly,
the baseline-adjusted AUC difference for IL-6 in plasma
was 18.6, compared with one standard deviation for the
combined data (17.2). Reductions in AUC for CSF and
plasma IL-8 and IL-10 were also seen, although again
the differences were not significant. Plasma CRP was
not affected by IL-1Ra over the 6- to 24-hour period,
but reduced over the following 24 hours in the IL-Ra
cohort, relative to placebo (Figure 3b).Clinical outcome
Although the study was not designed or powered to
measure clinical outcome, the Glasgow Outcome Score
(GOS) at 6 months was obtained from the clinical notes
and reported for each patient who received placebo or
IL-1Ra in the study (Table 6). There was no evidence of
difference between treatment groups.Discussion
We observed that IV IL-1Ra reduced the concentration
of IL-6 in CSF and plasma to the extent predicted, although
Singh et al. Journal of Neuroinflammation 2014, 11:1 Page 7 of 8
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that statistical significance could not be achieved. This
provides evidence that peripherally administered IL-1Ra
has a biological effect within the central nervous system
(CNS) after acute brain injury in humans. It is not cer-
tain whether IL-6 itself may be causally involved in
contributing to pathology, but both peripheral and central
IL-6 have been shown to be associated with outcome
[24,25]. However, here we have simply used it as a bio-
logical marker to monitor the level of inflammation
that results after SAH. Although we were interested in
how other markers might respond, we chose IL-6 at the
outset as the primary marker, to reduce the difficulty of
interpreting P values from multiple statistical analyses.
As such, the data support the rationale for developing
IL-1Ra as a therapy to attenuate the neuroinflammatory
response, and possibly the development of DCI, after SAH.
The higher IL-6 concentrations in CSF, compared to
plasma, are consistent with previous studies [26], and
indicate that changes in CSF do not result from IL-1Ra
altering peripheral IL-6 production before translocation
to the CNS. We had anticipated a lag in response to IL-
1Ra infusion, which is why the analysis is from 6 hours.
However, as shown by data for those patients where
data was available beyond 24 hours, the effect almost
certainly continues beyond this time point. Although
sample analysis at later times may demonstrate a greater
difference, we are reluctant to attribute significance on
the basis of post-hoc analysis, with missing data. Con-
centrations of CSF and plasma IL-1β and TNF were
very low or undetectable, as also found previously [26].
The other cytokines, IL-8, IL-10, and MCP-1 showed
differences in the direction expected if IL-1Ra was acting
in an anti-inflammatory manner but, as for IL-6, did
not reach statistical significance. Consistent with IL-6
as the major driver of the CRP response, plasma CRP
concentrations fell in the treatment group, relative to
placebo, but only after the primary analysis period.
The study was limited by the small number of patients,
mainly due to difficulties of recruiting from a cohort of
critically unwell patients. The treatment arm also had
patients with a higher WFNS, and started with a higher
median IL-6 value. This may have mitigated against
observing a treatment effect as more severe implies a
bigger drive to counter with therapeutic intervention.
The age and gender of patients, and aneurysm location,
was however representative of the SAH population as a
whole. In keeping with previous clinical studies involving
critically unwell patients, IV IL-1Ra was found to be
safe and no reported adverse events could be attributed
to the drug.
IL-1Ra is unique as a candidate for treatment of the
inflammatory response that is induced by SAH and there
are extensive preclinical and clinical pharmacokinetic datasupporting the role of IL-1Ra as a neuroprotective agent
[11]. This contrasts with other candidate treatments in
SAH, such as clazosentan and magnesium sulphate
(MgSO4), where the lack of patient pharmacokinetic
and pharmacodynamic data may partly explain the recent
failure of phase III clinical trials [27,28].
Conclusions
Reduction of IL-6 concentration in CSF of patients with
SAH indicates that IV administered IL-1Ra may act
within the CNS directly or indirectly to attenuate the
early inflammatory response to SAH. This suggests it is
a promising therapeutic option for the prevention of
inflammation and DCI in SAH. Larger trials are re-
quired in order to confirm its efficacy and impact on
clinical outcome.
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